The recent approval of omaveloxolone for the treatment of Friedreich ataxia in the USA and Europe represents an important milestone in the field of rare neurological diseases. However, many challenges lie ahead, including the translation of trial results into clinical practice, and the management of patients’ expectations.

中文翻译：

---

omaveloxolone 获批用于治疗 Friedreich 共济失调

最近在美国和欧洲批准 omaveloxolone 用于治疗 Friedreich 共济失调，这是罕见神经系统疾病领域的一个重要里程碑。然而，仍然存在许多挑战，包括将试验结果转化为临床实践以及患者期望的管理。